Neffy® (epinephrine nasal spray) was approved on August 9, 2024, for the emergency treatment of allergic reactions (type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients weighing at least 66 pounds.
For years, Humira® (adalimumab) has been a significant driver of healthcare costs due to its high price and utilization. With the introduction of several Humira biosimilars, learn how ClearScript has been monitoring the landscape and adapting strategies to provide members access to cost-effective therapy options for better health.
Why are the Big Three the most significant cost drivers in pharmacy benefits today? Because they put profits before patients. Fortunately, ClearScript is different. Listen to this coffee chat to learn how you can ensure your PBM is putting your members before profits.
Listen to learn why Tribal Nations are especially at risk when working with big PBMs that don’t keep their best interests at heart.
To help plans manage the rising cost of diabetes and weight management while improving member health, ClearScript offers our MedEmpower Fuel™ program.
On June 24, 2024, drug manufacturer Teva Pharmaceuticals announced the launch of an authorized generic formulation of Novo Nordisk’s Victoza (liraglutide). This marks the first generic glucagon-like peptide-1 (GLP-1) agonist available in the U.S. market.
ClearScript was an early pioneer of transparency in pharmacy benefit management. Unlike the Big Three PBMs, we put patients before profits.
With the rapid-fire launch of multiple new biosimilars, health plan managers struggle to understand the impact to their pharmacy benefit plan. Listen to get answers from ClearScript’s clinical account team on frequently asked questions about biosimilars.
GLP-1s are a hot topic in health plans due to their high-price tag and coverage complexity. Following up on ClearScript’s recent GLP-1 webinar, this podcast will answer some new questions and provide additional updates about this drug class.
On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.
With Humira® biosimilars expected to have a significant impact in 2024, some ClearScript clients are asking for more information. Here we provide the biosimilar basics and what their increasing presence in the marketplace means to the pharmacy benefit.
ClearScript’s Clinical Account Executives, Bryan Milbert, PharmD, and Nicole Christian, PharmD, provide a factual presentation on biosimilars’ history, outlook, and how these products could bend your cost curve including perspectives from plan sponsors, members, and prescribers.